Term
| Drugs that are highly lipid soluble are more likely to pass through the blood-brain barrier and reach the central nervous system. |
|
Definition
|
|
Term
| A patient is being seen in the emergency department for a sprained ankle and is given a drug to relieve pain. When a second dose of the pain medication is given, the patient develops redness of the skin, itching, and swelling at the site of injection of the drug. The most likely cause of this response is |
|
Definition
|
|
Term
A surgical patient has been diagnosed with type 2 diabetes during his current admission to the hospital. The nurses and other members of the care team have attempted to engage the patient in education about his new diagnosis, the effects it will have on his lifestyle and the medications that will be necessary to treat it. However, the patient is unwilling to discuss these matters, usually citing fatigue or the desire to watch TV or make phone calls. What potential nursing diagnosis should the nurse prioritize?
|
|
Definition
|
|
Term
| A nurse is responsible for maintaining an accurate count and record of the controlled substances on the nursing division. This nursing action is regulated by which of the following laws or agencies? |
|
Definition
|
|
Term
| The nurse is administering a medication to a patient who reports pain in her knees from arthritis. The nurse observes the name of the drug as p-isobutylhydratropic and recognizes that this refers to what type of name? |
|
Definition
|
|
Term
|
Definition
| drug effects that are not desired therapeutic effects; may be unpleasant or even dangerous |
|
|
Term
| The Food and Drug Administration regulates the development and sale of drugs. |
|
Definition
|
|
Term
| Rina is four months pregnant. She works in the chemical unit of a research department and is responsible for handling various chemicals. Her gynecologist advised her not to expose herself to chemical or industrial vapors and specific drugs. What is the reason for these restrictions? |
|
Definition
| Exposure to industrial vapors could damage the immature nervous system of the fetus. |
|
|
Term
| The right route of the drug is usually determined by the drug's formulation. |
|
Definition
|
|
Term
|
Definition
| involves use of the drug in vast clinical market. Drugs that finish this stage are evaluated by FDA for approval to market. The approved drug is given a brand name by the pharmaceutical company |
|
|
Term
|
Definition
| name givento a drug by the pharmaceutical company that developed it; also called a trade name |
|
|
Term
|
Definition
| name that reflects the chemical structure of a drug |
|
|
Term
|
Definition
Food and Drug Administration
federal agency responsible for the regulation and enforcement of drug evaluation and distribution policies |
|
|
Term
|
Definition
| drugs sold by their generic name; but not brand (trade) name products |
|
|
Term
|
Definition
| the original designation that a drug is given when the drug company that developed it & applies for the approval process |
|
|
Term
|
Definition
| process of altering DNA, usually of bacteria, to produce a chemical to be used as a drug |
|
|
Term
|
Definition
| drugs that have been discovered but would not be profitable for a drug company to develop; usually drugs taht would treat only a small number of people; these orphans can be adopted by drug companies to develop |
|
|
Term
|
Definition
| the study of the biological effects of chemicals |
|
|
Term
|
Definition
| clinical pharmacology; the branch of pharmacology that deals w/ drugs; chemicals that are used in medicine for the treatment, prevention, and diagnosis of disease in humans |
|
|
Term
|
Definition
| pilot study of a potential drug done w/ a small number of selected healthy human volunteers. Usually healthy young men |
|
|
Term
|
Definition
| chemicals that may have therapeutic value are tested on laboratory animals for two main purposes: 1. to determine whether they have the presumed effects in living tissue 2. to evaluate any adverse effects |
|
|
Term
|
Definition
| allows clinical investigators to try out the drug in patients who have the disease that the drug is designed to treat |
|
|
Term
|
Definition
|
|
Term
|
Definition
| phase of continual evaluation where prescribers are obligated to report to FDA any untoward or unexpected adverse effects. |
|
|
Term
| Who monitors the storing, prescribing and distribution of controlled substances |
|
Definition
|
|
